INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
11.73 USD
-0.02 (-0.17%)
11.73 USD
0 (0%)
IART gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
In the past year IART had a positive cash flow from operations.
Of the past 5 years IART 4 years were profitable.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.58%, IART is in line with its industry, outperforming 56.38% of the companies in the same industry.
IART has a Return On Equity (-47.74%) which is comparable to the rest of the industry.
IART has a Return On Invested Capital of 4.27%. This is in the better half of the industry: IART outperforms 73.94% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IART is below the industry average of 8.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
Looking at the Operating Margin, with a value of 10.22%, IART is in the better half of the industry, outperforming 77.13% of the companies in the same industry.
IART's Operating Margin has declined in the last couple of years.
IART has a Gross Margin of 57.21%. This is comparable to the rest of the industry: IART outperforms 55.85% of its industry peers.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IART is creating some value.
Compared to 1 year ago, IART has less shares outstanding
IART has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.23, we must say that IART is in the distress zone and has some risk of bankruptcy.
IART has a Altman-Z score of 1.23. This is comparable to the rest of the industry: IART outperforms 55.32% of its industry peers.
IART has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IART (1.73) is worse than 81.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.23 |
ROIC/WACC0.82
WACC5.23%
2.3 Liquidity
IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.14, IART is in the better half of the industry, outperforming 60.64% of the companies in the same industry.
IART has a Quick Ratio of 1.80. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.80, IART perfoms like the industry average, outperforming 46.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
The Revenue has been growing slightly by 4.99% in the past year.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 2.68% on average per year.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.39% yearly.
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 4.95, the valuation of IART can be described as very cheap.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.34% of the companies are valued more expensively.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.56.
Based on the Price/Forward Earnings ratio of 4.85, the valuation of IART can be described as very cheap.
Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 98.94% of the companies are valued more expensively.
IART's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.62.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.95 | ||
| Fwd PE | 4.85 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IART indicates a rather cheap valuation: IART is cheaper than 94.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.66 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.73
-0.02 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change0.01%
Ins Owners3.04%
Ins Owner Change0.07%
Market Cap913.88M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target17.34 (47.83%)
Short Float %10.31%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)3.48%
PT rev (3m)3.48%
EPS NQ rev (1m)-11.49%
EPS NQ rev (3m)-11.49%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)-5.75%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-1.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.95 | ||
| Fwd PE | 4.85 | ||
| P/S | 0.56 | ||
| P/FCF | N/A | ||
| P/OCF | 10.23 | ||
| P/B | 0.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.66 |
EPS(TTM)2.37
EY20.2%
EPS(NY)2.42
Fwd EY20.62%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY9.77%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.23 |
F-Score5
WACC5.23%
ROIC/WACC0.82
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.